Number of Regularly Prescribed Drugs and Intrapatient Tacrolimus Trough Levels Variability in Stable Kidney Transplant Recipients

被引:6
|
作者
Giza, Piotr [1 ]
Ficek, Rafal [1 ]
Dwulit, Tomasz [1 ]
Chudek, Jerzy [2 ]
Wozniak, Iwona [3 ]
Wiecek, Andrzej [1 ]
Kolonko, Aureliusz [1 ]
机构
[1] Med Univ Silesia, Dept Nephrol Transplantat & Internal Med, Francuska 20-24, PL-40027 Katowice, Poland
[2] Med Univ Silesia, Dept Internal Med & Oncol Chemotherapy, Reymonta 8, PL-40027 Katowice, Poland
[3] Med Univ Silesia, Univ Hosp, Francuska 20-24, PL-40027 Katowice, Poland
关键词
chronic kidney disease; coefficient of variation; co-medication; drug interactions; number of medications; extended-release tacrolimus; tacrolimus formulation; ONCE-DAILY TACROLIMUS; RENAL-FUNCTION; PILL BURDEN; REJECTION; RISK; MEDICATION; CONVERSION; EXPOSURE;
D O I
10.3390/jcm9061926
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High intra-patient variability (IPV) of tacrolimus levels is associated with poor long-term outcome after transplantation. We aimed to evaluate whether the number of regularly prescribed medications is associated with the tacrolimus IPV. We have studied 152 kidney transplant recipients (KTRs) with mean post-transplant time of 6.0 +/- 3.1 years. The coefficient of variation (CV) as a measure of IPV was calculated in each individual patient. Data concerning the type and number of currently prescribed medications were collected. The participants were divided into four groups, based on the number of regularly prescribed drugs (<= 3, 4-6, 7-9, >= 10 drugs, respectively). There was an increasing trend for median CV, proportional to the increasing number of medications [group 1: 0.11 (interquartile range, 0.08-0.14), group 2: 0.14 (0.01-0.17), group 3: 0.17 (0.14-0.23), group 4: 0.17 (0.15-0.30);pvalue for trend = 0.001]. Stepwise backward multivariate regression analysis revealed that the number of medications [partial correlation coefficient (r(partial)) = 0.503,p< 0.001] independently influenced the tacrolimus IPV. Concomitant steroid or diuretics use increased IPV only in Advagraf-treated KTRs, whereas proton-pump inhibitor or statin use increased IPV in the Prograf group but not in the Advagraf group. A large number of concomitant medications significantly increases the tacrolimus IPV in stable KTRs.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] IMPACT OF TACROLIMUS TROUGH LEVEL IN KIDNEY TRANSPLANT RECIPIENTS ON THE POST-TRANSPLANT CLINICAL OUTCOME
    Park, Woo Yeong
    Park, Ha Yeon
    Yeo, Sang Mok
    Kang, Seong Sik
    Park, Sung Bae
    Yoon, Jeongsoo
    Jin, Kyubok
    Han, Seungyeup
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [42] Impact of once-daily tacrolimus on trough concentration variability in stable adolescent and young adult renal transplant recipients
    Moss, Mary
    Goebel, Jens
    Steinberg, Elizabeth
    Bock, Margret
    PEDIATRIC TRANSPLANTATION, 2019, 23
  • [43] Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients
    Cheng, C. -Y.
    Wu, M. -J.
    Lin, C. -C.
    Hou, Y. -C.
    Liou, W. -S.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (08) : 2401 - 2403
  • [44] Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study
    Zheng, YuanPu
    Masand, Anjali
    Wagner, Michael
    Kapur, Sandip
    Dadhania, Darshana
    Lubetzky, Michelle
    Lee, John Richard
    TRANSPLANTATION DIRECT, 2019, 5 (09):
  • [45] Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure
    Sapir-Pichhadze, Ruth
    Wang, Yao
    Famure, Olusegun
    Li, Yanhong
    Kim, S. Joseph
    KIDNEY INTERNATIONAL, 2014, 85 (06) : 1404 - 1411
  • [46] Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients
    Tornatore, Kathleen M.
    Meaney, Calvin J.
    Attwood, Kristopher
    Brazeau, Daniel A.
    Wilding, Gregory E.
    Consiglio, Joseph D.
    Gundroo, Aijaz
    Chang, Shirley S.
    Gray, Vanessa
    Cooper, Louise M.
    Venuto, Rocco C.
    PHARMACOTHERAPY, 2022, 42 (02): : 94 - 105
  • [47] Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients
    Wu, Sheng-Wen
    Tsai, Hui-Ching
    Tsai, Pao-Yu
    Hung, Tung-Wei
    Chang, Horng-Rong
    Lian, Jong-Da
    SWISS MEDICAL WEEKLY, 2013, 143
  • [48] Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus
    Amanova, Anara
    Celebi, Zeynep Kendi
    Bakar, Filiz
    Caglayan, Mehmet G.
    Keven, Kenan
    CLINICAL TRANSPLANTATION, 2014, 28 (10) : 1177 - 1183
  • [49] COLCHICINE LEVELS IN CHRONIC KIDNEY DISEASES AND KIDNEY TRANSPLANT RECIPIENTS USING TACROLIMUS
    Amanova, Anara
    Celebi, Zeynep Kendi
    Bakar, Filiz
    Caglayan, Mehmet Gokhan
    Keven, Kenan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 317 - 318
  • [50] Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients
    In-Wha Kim
    Yoo Jin Moon
    Eunhee Ji
    Kyung Im Kim
    Nayoung Han
    Sung Ju Kim
    Wan Gyoon Shin
    Jongwon Ha
    Jeong-Hyun Yoon
    Hye Suk Lee
    Jung Mi Oh
    European Journal of Clinical Pharmacology, 2012, 68 : 657 - 669